LICORbio Enhances Offerings with SERVA Electrophoresis Acquisition

LICORbio Expands Portfolio with Strategic Acquisition of SERVA Electrophoresis

LICORbio, a pioneer in life science imaging and analytical solutions, has made a significant move to enhance its offerings by acquiring SERVA Electrophoresis. This strategic acquisition, announced on July 1, 2025, positions LICORbio as a more comprehensive solutions provider in the field of protein analysis. SERVA, renowned for its superior electrophoresis reagents, consumables, and workflow instrumentation, complements LICORbio’s existing portfolio, thus paving the way for innovation in life sciences research.

Expanding Capabilities in Proteomics

With the acquisition of SERVA, LICORbio is poised to broaden its electrophoresis offerings significantly. This strategic addition allows LICORbio to present an end-to-end workflow solution aimed at fulfilling the evolving needs of proteomics researchers globally. The integration of SERVA's proprietary technologies into LICORbio's industry-leading imaging platforms will result in a complete workflow, encompassing sample preparation, resolution, imaging, and quantification, thus offering users high-quality tools throughout their research process.

Tom Reslewic, the CEO of LICORbio, emphasized this acquisition's importance, stating, “This acquisition reflects LICORbio's strategic focus on expanding our core technologies while staying close to the needs of the research community.” By marrying SERVA’s extensive electrophoresis products with LICORbio's imaging systems, the company aims to provide more accurate and efficient workflows for protein, DNA, and RNA analyses.

A Bright Future for Collaboration

Bambi Reynolds, LICORbio's senior vice president and general manager, expressed excitement over the merger, articulating how this acquisition is not merely about expanding product lines but also about forging integrated solutions and merging dedicated teams committed to scientific advancement. The enthusiasm within the teams underscores the organization's forward-looking approach, focusing on innovation, collaboration, and customer satisfaction.

SERVA, established in 1953, has developed a strong reputation for innovation in gel electrophoresis. Its extensive catalog of reagents and consumables is known for delivering robust performance across various applications, and its technology synergistically aligns with LICORbio's mission of empowering discovery through accessible and top-notch research tools.

Seamless Integration and Future Outlook

The integration of SERVA into LICORbio’s operations is already underway, and the acquisition will honor SERVA's legacy by maintaining its Heidelberg location, thereby leveraging LICORbio's global infrastructure for enhanced support. Customers can anticipate uninterrupted access to SERVA's full range of products, coupled with improved service and integrated imaging solutions.

Licor bio, with its dedication to innovation in proteomics, genomics, and cell biology, continues to uphold a tradition of delivering solutions that accelerate discovery and increase reproducibility in research environments. The expansion of their portfolio promises to not only enhance their service offerings but also to push the boundaries of scientific research forward.

Conclusion

As LICORbio integrates SERVA's high-quality products into its lineup, the scientific community can look forward to an enriched suite of tools that promise to streamline research processes and enhance discovery outcomes. The future of this partnership holds great potential as both companies work together to provide researchers with cutting-edge solutions in life sciences. For further information, visit LICORbio.